Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Anticancer autophagy inhibitors attract ‘resurgent’ interest

Despite industry’s past setbacks with autophagy inhibitors, preclinical and clinical findings are starting to revitalize a once written-off strategy.
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed  Google Scholar

Credit: Vicky Summersby/Springer Nature Limited

The idea of targeting autophagy, the cell’s recycling process, to treat cancer is experiencing a comeback. Years after most large pharmaceutical companies abandoned the therapeutic strategy for oncology applications, several academic groups and fledgling companies have begun zeroing in on cancer types and drug regimens in which autophagy inhibition may still hold promise.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 408-410 (2019)

doi: https://doi.org/10.1038/d41573-019-00072-1

Updates & Corrections

  • Correction 01 May 2019: The text describing a single-arm skin cancer study evaluating trametinib plus Novartis’s BRAF inhibitor dabrafenib with the addition of hydroxychloroquine for patients with BRAF-mutant melanoma has been revised to reflect that the study is still ongoing rather than completed.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links